TSC2 and prostate cancer: However, by using logistic regression strategy, we found and validated that several VUS-containing genes (COL1A1, CSF3R, ERBB2, ITGB8, TSC1 and TSC2) in the PI3K-Akt signaling pathway can improve the predicting of metastasis in prostate cancer patients in Hong Kong and Shanghai cohorts.